Cargando…
Clinical Outcomes of Diabetic Ketoacidosis in Type 2 Diabetes Patients with and without SGLT2 Inhibitor Treatment: A Retrospective Study
Aim: This study aimed to compare the clinical course and outcomes of DKA in T2DM patients who received treatment with SGLT2 inhibitors versus those who did not. Methods: A retrospective analysis was conducted on T2DM patients who were admitted to the Rambam Health Care Campus with DKA between 7/2015...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604468/ https://www.ncbi.nlm.nih.gov/pubmed/37893063 http://dx.doi.org/10.3390/biomedicines11102689 |
_version_ | 1785126842667106304 |
---|---|
author | Nakhleh, Afif Othman, Areen Masri, Amin Zloczower, Moshe Zolotov, Sagit Shehadeh, Naim |
author_facet | Nakhleh, Afif Othman, Areen Masri, Amin Zloczower, Moshe Zolotov, Sagit Shehadeh, Naim |
author_sort | Nakhleh, Afif |
collection | PubMed |
description | Aim: This study aimed to compare the clinical course and outcomes of DKA in T2DM patients who received treatment with SGLT2 inhibitors versus those who did not. Methods: A retrospective analysis was conducted on T2DM patients who were admitted to the Rambam Health Care Campus with DKA between 7/2015 and 9/2020. Demographic, clinical, and laboratory data were obtained from electronic medical records. Outpatient mortality was monitored until 12/2022. Results: Of 71 T2DM patients admitted with DKA, 16 (22.5%) were on SGLT2 inhibitor treatment upon admission. SGLT2 inhibitor users had a higher BMI and were less likely to be treated with insulin. During hospitalization, the rates of acute kidney injury, concomitant infections, and inpatient mortality among SGLT2 inhibitor users were comparable to non-users. The median follow-up period was 35.1 months for the SGLT2 inhibitor users and 36.7 months for non-users. The long-term mortality from any cause was lower among the SGLT2 inhibitor users (12.5% vs. 52.7%, p = 0.004). In Cox regression analysis, SGLT2 inhibitor use was associated with a lower risk of long-term mortality from any cause (HR = 0.19, p = 0.04). Conclusion: T2DM patients with DKA who received SGLT2 inhibitors had lower long-term mortality from any cause compared to those who did not receive SGLT2 inhibitors. |
format | Online Article Text |
id | pubmed-10604468 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106044682023-10-28 Clinical Outcomes of Diabetic Ketoacidosis in Type 2 Diabetes Patients with and without SGLT2 Inhibitor Treatment: A Retrospective Study Nakhleh, Afif Othman, Areen Masri, Amin Zloczower, Moshe Zolotov, Sagit Shehadeh, Naim Biomedicines Article Aim: This study aimed to compare the clinical course and outcomes of DKA in T2DM patients who received treatment with SGLT2 inhibitors versus those who did not. Methods: A retrospective analysis was conducted on T2DM patients who were admitted to the Rambam Health Care Campus with DKA between 7/2015 and 9/2020. Demographic, clinical, and laboratory data were obtained from electronic medical records. Outpatient mortality was monitored until 12/2022. Results: Of 71 T2DM patients admitted with DKA, 16 (22.5%) were on SGLT2 inhibitor treatment upon admission. SGLT2 inhibitor users had a higher BMI and were less likely to be treated with insulin. During hospitalization, the rates of acute kidney injury, concomitant infections, and inpatient mortality among SGLT2 inhibitor users were comparable to non-users. The median follow-up period was 35.1 months for the SGLT2 inhibitor users and 36.7 months for non-users. The long-term mortality from any cause was lower among the SGLT2 inhibitor users (12.5% vs. 52.7%, p = 0.004). In Cox regression analysis, SGLT2 inhibitor use was associated with a lower risk of long-term mortality from any cause (HR = 0.19, p = 0.04). Conclusion: T2DM patients with DKA who received SGLT2 inhibitors had lower long-term mortality from any cause compared to those who did not receive SGLT2 inhibitors. MDPI 2023-10-01 /pmc/articles/PMC10604468/ /pubmed/37893063 http://dx.doi.org/10.3390/biomedicines11102689 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Nakhleh, Afif Othman, Areen Masri, Amin Zloczower, Moshe Zolotov, Sagit Shehadeh, Naim Clinical Outcomes of Diabetic Ketoacidosis in Type 2 Diabetes Patients with and without SGLT2 Inhibitor Treatment: A Retrospective Study |
title | Clinical Outcomes of Diabetic Ketoacidosis in Type 2 Diabetes Patients with and without SGLT2 Inhibitor Treatment: A Retrospective Study |
title_full | Clinical Outcomes of Diabetic Ketoacidosis in Type 2 Diabetes Patients with and without SGLT2 Inhibitor Treatment: A Retrospective Study |
title_fullStr | Clinical Outcomes of Diabetic Ketoacidosis in Type 2 Diabetes Patients with and without SGLT2 Inhibitor Treatment: A Retrospective Study |
title_full_unstemmed | Clinical Outcomes of Diabetic Ketoacidosis in Type 2 Diabetes Patients with and without SGLT2 Inhibitor Treatment: A Retrospective Study |
title_short | Clinical Outcomes of Diabetic Ketoacidosis in Type 2 Diabetes Patients with and without SGLT2 Inhibitor Treatment: A Retrospective Study |
title_sort | clinical outcomes of diabetic ketoacidosis in type 2 diabetes patients with and without sglt2 inhibitor treatment: a retrospective study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604468/ https://www.ncbi.nlm.nih.gov/pubmed/37893063 http://dx.doi.org/10.3390/biomedicines11102689 |
work_keys_str_mv | AT nakhlehafif clinicaloutcomesofdiabeticketoacidosisintype2diabetespatientswithandwithoutsglt2inhibitortreatmentaretrospectivestudy AT othmanareen clinicaloutcomesofdiabeticketoacidosisintype2diabetespatientswithandwithoutsglt2inhibitortreatmentaretrospectivestudy AT masriamin clinicaloutcomesofdiabeticketoacidosisintype2diabetespatientswithandwithoutsglt2inhibitortreatmentaretrospectivestudy AT zloczowermoshe clinicaloutcomesofdiabeticketoacidosisintype2diabetespatientswithandwithoutsglt2inhibitortreatmentaretrospectivestudy AT zolotovsagit clinicaloutcomesofdiabeticketoacidosisintype2diabetespatientswithandwithoutsglt2inhibitortreatmentaretrospectivestudy AT shehadehnaim clinicaloutcomesofdiabeticketoacidosisintype2diabetespatientswithandwithoutsglt2inhibitortreatmentaretrospectivestudy |